A recently published study reported that ADCs targeting the tight junction protein claudin-1 (CLDN1) could be relevant to circumvent acquired resistance to chemotherapy and improve outcome in patients with advanced colon cancer [285]. Here, CLDN1 is linked to malignant colon neoplasm.